Literature DB >> 12114668

Immunohistochemical Localization of p53 in Human Thyroid Neoplasms: Correlation with Biological Behavior.

Sefik A. Hosal1, Robyn L. Apel, Jeremy L. Freeman, Abbas Azadian, Irving B. Rosen, Virginia A. LiVolsi, Sylvia L. Asa.   

Abstract

Molecular analyses of thyroid tumors have documented mutations in the tumor suppressor p53 gene almost exclusively in anaplastic carcinomas. In contrast, immunohistochemistry has localized p53 in differentiated papillary and follicular thyroid cancers. To establish the significance of p53 immunolocalization in these lesions, 78 thyroid tumors of follicular derivation were examined. All tumors were classified by strict criteria and the extent of tumor was determined morphologically. Immunohistochemical staining for p53 was performed on paraffin sections of formalin-fixed tumor tissue. The results of staining were correlated with diagnosis, tumor extent and clinical outcome. Immunopositivity for p53 was diffuse and strong in all five anaplastic carcinomas examined. There was no staining in five of six follicular adenomas. Four of nine follicular carcinomas had some degree of nuclear staining, but this was focal; all nine tumors were confined to the thyroid at the time of examination. Of 49 papillary carcinomas, 26 were intrathyroidal, and 7 of these were occult; there was no p53 positivity in any occult lesion and only S of the 19 palpable lesions stained. In contrast, among 23 papillary carcinomas with extra thyroidal extension or metastases, only 9 were negative for p53 immunoreactivity. Five of seven tall cell papillary carcinomas and one of two insular carcinomas had p53 immunopositivity and this correlated with aggressive behavior. These results support the tumorigenic role of p53 mutations postulated for anaplastic thyroid carcinomas and indicate that localization of p53 by immunohistochemistry is a useful prognostic index of clinical behavior in differentiated thyroid carcinomas of follicular cell derivation.

Entities:  

Year:  1997        PMID: 12114668     DOI: 10.1007/bf02739704

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  20 in total

1.  P53 in tumour pathology: can we trust immunocytochemistry?

Authors:  D Wynford-Thomas
Journal:  J Pathol       Date:  1992-04       Impact factor: 7.996

2.  The p53 tumor-suppressor gene.

Authors:  A J Levine
Journal:  N Engl J Med       Date:  1992-05-14       Impact factor: 91.245

3.  Overexpression of p53 protein in basal cell carcinomas of human skin.

Authors:  C R Shea; N S McNutt; M Volkenandt; J Lugo; P G Prioleau; A P Albino
Journal:  Am J Pathol       Date:  1992-07       Impact factor: 4.307

4.  Mutations in the p53 gene occur in diverse human tumour types.

Authors:  J M Nigro; S J Baker; A C Preisinger; J M Jessup; R Hostetter; K Cleary; S H Bigner; N Davidson; S Baylin; P Devilee
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

5.  p53 mutations in all stages of thyroid carcinomas.

Authors:  M Zou; Y Shi; N R Farid
Journal:  J Clin Endocrinol Metab       Date:  1993-10       Impact factor: 5.958

6.  Immunohistochemical detection of p53 in differentiated, poorly differentiated and undifferentiated carcinomas of the thyroid.

Authors:  P Soares; J Cameselle-Teijeiro; M Sobrinho-Simões
Journal:  Histopathology       Date:  1994-03       Impact factor: 5.087

7.  Assessment of p53 protein expression in normal, benign, and malignant oral mucosa.

Authors:  G R Ogden; R A Kiddie; D P Lunny; D P Lane
Journal:  J Pathol       Date:  1992-04       Impact factor: 7.996

Review 8.  Tumor suppressor genes.

Authors:  R A Weinberg
Journal:  Science       Date:  1991-11-22       Impact factor: 47.728

9.  Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland.

Authors:  R Donghi; A Longoni; S Pilotti; P Michieli; G Della Porta; M A Pierotti
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

10.  p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas.

Authors:  T Nakamura; I Yana; T Kobayashi; E Shin; K Karakawa; S Fujita; A Miya; T Mori; I Nishisho; S Takai
Journal:  Jpn J Cancer Res       Date:  1992-12
View more
  8 in total

1.  Decreased expression of p27 is associated with malignant transformation and extrathyroidal extension in papillary thyroid carcinoma.

Authors:  Sung-Im Do; Dong Hyun Kim; Jung-Ho Yang; Jung-Soo Pyo; Kyungeun Kim; Hyunjoo Lee; In-Gu Do; Dong-Hoon Kim; Seoung Wan Chae; Jin Hee Sohn
Journal:  Tumour Biol       Date:  2015-10-07

Review 2.  An evidence-based review of poorly differentiated thyroid cancer.

Authors:  Enoch M Sanders; Virginia A LiVolsi; James Brierley; Jennifer Shin; Gregory W Randolph
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

3.  The neutrophil to lymphocyte ratio can discriminate anaplastic thyroid cancer against poorly or well differentiated cancer.

Authors:  Jin-Seong Cho; Min-Ho Park; Young-Jae Ryu; Jung-Han Yoon
Journal:  Ann Surg Treat Res       Date:  2015-03-26       Impact factor: 1.859

Review 4.  Lessons from mouse models of thyroid cancer.

Authors:  Caroline S Kim; Xuguang Zhu
Journal:  Thyroid       Date:  2009-12       Impact factor: 6.568

5.  Villous papillary thyroid carcinoma: a variant associated with marfan syndrome.

Authors:  Daniel A Winer; Shawn Winer; Lorne Rotstein; Sylvia L Asa; Ozgur Mete
Journal:  Endocr Pathol       Date:  2012-12       Impact factor: 3.943

Review 6.  Modeling thyroid cancer in the mouse.

Authors:  X-G Zhu; S-Y Cheng
Journal:  Horm Metab Res       Date:  2009-04-08       Impact factor: 2.936

7.  Clinical significance of p53 protein expression in papillary thyroid carcinoma.

Authors:  Naomi Morita; Yoshifumi Ikeda; Hiroshi Takami
Journal:  World J Surg       Date:  2008-12       Impact factor: 3.352

8.  Familial adenomatous polyposis-associated thyroid cancer: a clinical, pathological, and molecular genetics study.

Authors:  C Soravia; S L Sugg; T Berk; A Mitri; H Cheng; S Gallinger; Z Cohen; S L Asa; B V Bapat
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.